| Literature DB >> 27303691 |
Tara Rema1, Prabhakara Medihala1, John R Lawrence2, Sinisa Vidovic3, Gary G Leppard4, Marcia Reid5, Darren R Korber1.
Abstract
Protein expression and fatty acid profiles of biofilm cells of chlorhexidine-tolerant Delftia acidovorans (MIC = 15 µg/ml) and its chlorhexidine-susceptible mutant (MIC = 1 µg/ml) were investigated. The chlorhexidine-susceptible mutant (MT51) was derived from the parental strain (WT15) using Tn5 transposon mutagenesis. The disrupted gene was identified as tolQ, a component of the tolQRAB gene cluster known to be involved in outer membrane stability. Proteomic responses of biofilm cells were compared by differential in-gel electrophoresis following exposure to chlorhexidine at sub-MIC (10 µg/ml) and above-MIC (30 µg/ml) concentrations. Numerous changes in protein abundance were observed in biofilm cells following chlorhexidine exposure, suggesting that molecular changes occurred during adaptation to chlorhexidine. Forty proteins showing significant differences (≥1.5-fold; P < 0.05) were identified by mass spectrometry and were associated with various functions, including amino acid and lipid biosynthesis, protein translation, energy metabolism, and stress-related functions (e.g., GroEL, aspartyl/glutamyl-tRNA amidotransferase, elongation factor Tu, Clp protease, and hydroxymyristoyl-ACP dehydratase). Several proteins involved in fatty acid synthesis were affected by chlorhexidine, in agreement with fatty acid analysis, wherein chlorhexidine-induced shifts in the fatty acid profile were observed in the chlorhexidine-tolerant cells, primarily the cyclic fatty acids. Transmission electron microscopy revealed more prominent changes in the cell envelope of chlorhexidine-susceptible MT51 cells. This study suggests that multiple mechanisms involving both the cell envelope (and likely TolQ) and panmetabolic regulation play roles in chlorhexidine tolerance in D. acidovorans. IMPORTANCE Delftia acidovorans has been associated with a number of serious infections, including bacteremia, empyema, bacterial endocarditis, and ocular and urinary tract infections. It has also been linked with a variety of surface-associated nosocomial infections. Biofilm-forming antimicrobial-resistant D. acidovorans strains have also been isolated, including ones displaying resistance to the common broad-spectrum agent chlorhexidine. The mechanisms of chlorhexidine resistance in D. acidovorans are not known; hence, a chlorhexidine-susceptible mutant of the tolerant wild-type strain was obtained using transposon mutagenesis, and the proteome and ultrastructural changes of both strains were compared under chlorhexidine challenge.Entities:
Keywords: Delftia acidovorans; biofilms; chlorhexidine tolerance; protein expression; tolQ
Year: 2016 PMID: 27303691 PMCID: PMC4863599 DOI: 10.1128/mSphere.00017-15
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
Results of antibiotic and chlorhexidine susceptibility testing for D. acidovorans strains WT51 (wild type) and MT51 (mutant)
| Antibiotic | MIC (µg/ml) | |
|---|---|---|
| Wild type | Mutant | |
| Amikacin | 64 | 16 |
| Chloramphenicol | 16 | 16 |
| Cefoxitin | <0.5 | <0.5 |
| Tetracycline | <4.0 | <4.0 |
| Ceftriaxone | <0.25 | 0.5 |
| Amoxicillin | 1 | 1 |
| Clavulanic acid | 0.5 | 0.5 |
| Ciprofloxacin | 0.25 | 0.12 |
| Gentamicin | 16 | 16 |
| Nalidixic acid | 0.5 | 0.5 |
| Ceftiofur | 0.5 | 0.5 |
| Sulfisoxazole | 32 | 32 |
| Trimethoprim | 0.12 | 0.12 |
| Sulfamethoxazole | 2.38 | 2.38 |
| Kanamycin | 64 | 64 |
| Ampicillin | 32 | 32 |
| Streptomycin | 64 | 64 |
| Chlorhexidine | 15 | 1 |
Compound for which a difference in MIC was observed.
FIG 1 TEM micrographs of 48 h D. acidovorans biofilm cells with and without exposure to 10 and 30 µg/ml chlorhexidine after 24 h of growth. (A) WT15 control; (B) MT51 control; (C) WT15 treated with chlorhexidine at 10 µg/ml; (D) MT51 treated with chlorhexidine at 10 µg/ml; (E) WT15 treated with chlorhexidine at 30 µg/ml; (F) MT51 treated with chlorhexidine at 30 µg/ml. Arrowheads show membrane structural alterations. Bar, 500 nm.
FIG 2 Relative amounts of fatty acid methyl esters, determined using gas chromatography, found in chlorhexidine-tolerant (WT15) and chlorhexidine-susceptible (MT51) D. acidovorans biofilm cells treated with (10 µg/ml with chlorhexidine) compared with the untreated control. CFA, cyclo fatty acids; UFA, unsaturated fatty acids; SFA, saturated fatty acids.
FIG 3 Principal component analysis of the 18 individual DIGE expression spot maps (6 treatments with three replications per treatment) differentiated by principal components one and two. Statistical analyses of PCA scores generated from the first two component axes were run using an analysis of similarity (ANOSIM) with PRIMER v6 software. M10 and M30 are the mutant strain treated with 10 and 30 µg/ml chlorhexidine, respectively; W10 and W30 are the wild-type strain treated with 10 and 30 µg/ml chlorhexidine, respectively; MC and WC are the mutant and wild-type controls, respectively.
Comparison data of differentially expressed proteins (≥1.5-fold increase/decrease; P < 0.05) among various experimental groups
| Groups | No. of proteins | Greatest | ||||
|---|---|---|---|---|---|---|
| Differentially | Picked for | With | With | Increase | Decrease | |
| MC and WC | 114 | 25 | 70 | 44 | 6.28 | 15.19 |
| W10 and WC | 105 | 26 | 53 | 52 | 6.25 | 7.54 |
| W30 and WC | 83 | 27 | 49 | 34 | 14.87 | 7.49 |
| M10 and MC | 107 | 30 | 63 | 44 | 7.62 | 4.47 |
| M30 and MC | 119 | 39 | 69 | 50 | 7.0 | 7.14 |
| M10 and W10 | 138 | 40 | 92 | 46 | 5.4 | 5.75 |
| M30 and W30 | 111 | 30 | 39 | 72 | 4.43 | 8.26 |
| W30 and W10 | 9 | 4 | 5 | 4 | 2.36 | 2.77 |
| M30 and M10 | 56 | 11 | 30 | 26 | 2.25 | 3.62 |
| 2-way ANOVA | 60 | 13 | NA | NA | NA | NA |
| 2-way ANOVA | 106 | 31 | NA | NA | NA | NA |
| 2-way ANOVA | 54 | 14 | NA | NA | NA | NA |
NA, not applicable.
FIG 4 Number of up-regulated and down-regulated proteins among various levels of significant change between various experimental groups. Red bars, up-regulated proteins; blue bars, down-regulated proteins. A, B, C, and D represent 2- to 3-fold, 3- to 5-fold, 5- to 10-fold, and >10-fold changes, respectively (P < 0.05). M10 and M30 are the mutant strain treated with 10 and 30 µg/ml chlorhexidine, respectively; W10 and W30 are the wild-type strain treated with 10 and 30 µg/ml chlorhexidine, respectively; MC and WC are the mutant and wild-type controls, respectively.
Protein expression changes in 48 h D. acidovorans WT15 and MT51 biofilms following chlorhexidine treatment at 0, 10 (W10 and M10), and 30 (W30 and M30) µg/ml after 24 h of biofilm growth
| Biological process and spot no. | Protein | Accession no. | Mass | pI | Fold change | 2-way ANOVA | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MC/WC | W10 | W30 | M10 | M30 | M10/W10 | M30/W30 | ||||||
| Generation of precursor metabolites and energy (GO:0006091) | ||||||||||||
| 115 | ATP synthase subunit alpha | gi|160895867 | 55,205 | 5.64 | +4.07 | +2.76 | +2.91 | NS | NS | NS | +2.16 | S, T, I |
| 122 | ATP synthase subunit alpha | gi|160895867 | 55,205 | 5.64 | +2.81 | +1.90 | +2.45 | NS | +1.81 | +2.07 | +2.07 | S, T, I |
| 125 | ATP synthase subunit beta | gi|160895869 | 50,633 | 5.23 | +2.68 | +2.22 | +3.08 | NS | +2.84 | +1.98 | +2.48 | S, T, I |
| 995 | ATP synthase subunit beta | gi|160895869 | 50,633 | 5.23 | +2.01 | +2.12 | +2.24 | +1.88 | +1.75 | +1.79 | NS | S, T |
| 589 | Ubiquinol-cytochrome | gi|160900935 | 21,695 | 6.1 | NS | −1.84 | −2.80 | NS | NS | NS | NS | T, I |
| 200 | Enolase | gi|160900540 | 45,951 | 4.82 | +2.24 | +2.92 | +3.27 | +2.98 | +3.54 | +2.29 | +2.43 | S, T |
| Fatty acid metabolic process (GO:0006631) | ||||||||||||
| 478 | Malonyl CoA-acyl carrier protein transacylase | gi|160900703 | 34,368 | 5.32 | +2.21 | +1.35 | +1.82 | NS | NS | NS | NS | S, T |
| 770 | (3 | gi|160900369 | 16,579 | 5.92 | NS | NS | NS | +1.72 | +2.22 | NS | NS | S, T, I |
| 563 | Enoyl-CoA hydratase/isomerase | gi|160896976 | 27,994 | 5.39 | +2.50 | NS | NS | −2.63 | −3.82 | NS | NS | T, I |
| 371 | Basic membrane lipoprotein | gi|160897585 | 41,068 | 5.71 | NS | +3.30 | +6.33 | +7.62 | +6.20 | NS | NS | S, T, I |
| Nucleotide biosynthetic process (GO:0009165) | ||||||||||||
| 606 | Glutamine amidotransferase | gi|160899150 | 25,022 | 5.72 | −15.19 | −3.63 | −3.42 | NS | NS | −5.09 | −3.46 | S, T, I |
| 218 | Amidohydrolase | gi|160897029 | 45,940 | 5.03 | NS | +2.11 | +2.43 | +1.92 | +2.16 | NS | NS | S, T |
| 91 | Bifunctional phosphoribosylaminoimidazole-carboxamide formyltransferase/IMP cyclohydrolase | gi|160897011 | 57,189 | 5.72 | +2.26 | +1.79 | +2.18 | NS | NS | NS | NS | S, T |
| Molecular chaperones / protein folding (GO:0006457) | ||||||||||||
| 877 | FKBP-type peptidylprolyl isomerase | gi|160900492 | 12,314 | 5.23 | −2.02 | −1.73 | −1.53 | NS | NS | −1.59 | −1.83 | S, T |
| 544 | PpiC-type peptidyl-prolyl | gi|160898739 | 28,914 | 8.5 | −1.69 | NS | NS | −1.50 | −2.33 | −1.93 | −2.58 | S, T |
| 886 | Heat shock protein HSP20 | gi|160897822 | 13,608 | 5.78 | −9.43 | −7.54 | −7.49 | NS | NS | S, T, I | ||
| 59 | 60-kDa chaperonin | gi|160901092 | 57,123 | 5.02 | NS | +1.85 | +3.36 | +3.35 | + 7.0 | +1.59 | +1.84 | S, T, I |
| 85 | 60-kDa chaperonin | gi|160901092 | 57,123 | 5.02 | NS | NS | NS | NS | +2.92 | +2.05 | +2.14 | S, T, I |
| 86 | 60-kDa chaperonin | gi|160901092 | 57,123 | 5.02 | NS | NS | NS | +2.03 | +2.49 | +1.77 | +1.89 | S, T, I |
| Translation/transcription (GO:0006412/0006351) | ||||||||||||
| 95 | Aspartyl/glutamyl-tRNA amidotransferase subunit A | gi|160895801 | 52,727 | 5.51 | +2.30 | +2.47 | +2.65 | +2.19 | +2.35 | +2.04 | NS | S, T |
| 190 | Elongation factor Tu | gi|160895838 | 43,296 | 5.48 | NS | +2.06 | +2.38 | +2.53 | +3.25 | NS | +2.42 | S, T, I |
| 274 | Elongation factor Tu | gi|160895838 | 43,296 | 5.48 | NS | +3.81 | +4.31 | NS | +2.01 | NS | NS | T, I |
| 436 | Elongation factor Ts | gi|160900379 | 31,142 | 5.5 | NS | NS | +2.07 | +1.76 | +2.06 | NS | NS | T |
| 629 | Two-component LuxR family transcriptional regulator | gi|160899416 | 23,896 | 5.87 | NS | −1.64 | −1.97 | NS | NS | NS | NS | S, T, I |
| Electron carrier activity (GO:0009055) | ||||||||||||
| 292 | Taurine catabolism dioxygenase TauD/TfdA | gi|160900189 | 37,395 | 5.17 | NS | +2.17 | +2.49 | NS | NS | −1.83 | NS | S, T, I |
| 612 | Electron transfer flavoprotein subunit alpha/beta | gi|160896849 | 26,734 | 7.64 | NS | NS | +1.66 | +1.96 | +3.08 | +1.57 | +1.67 | |
| Oxygen and reactive oxygen species metabolic process (GO:0006800) | ||||||||||||
| 662 | Superoxide dismutase | gi|160899011 | 21,614 | 5.87 | NS | −3.76 | −4.56 | NS | NS | NS | +3.39 | S, T, I |
| 647 | Superoxide dismutase | gi|16089811 | 22797 | 5.86 | −2.19 | NS | NS | NS | NS | NS | −3.62 | |
| 644 | Hypothetical protein (alkylhydroperoxidase-like protein, AhpD family) | gi|160899719 | 23,967 | 5.87 | NS | NS | NS | −3.03 | NS | −2.92 | NS | S, T, I |
| Proteolysis (GO:0006508) | ||||||||||||
| 658 | ATP-dependent Clp protease proteolytic subunit | gi|160898086 | 22,274 | 5.45 | NS | NS | +1.49 | +1.77 | +1.87 | NS | NS | S, T, I |
| 75 | Hypothetical protein (peptidase dimerization domain protein) | gi|160896656 | 62,743 | 7.08 | NS | NS | NS | −2.66 | −2.48 | −2.58 | −2.51 | S, T, I |
| Antibiotic metabolic process (GO:0016999) | ||||||||||||
| 536 | Hydroxyacylglutathione hydrolase | gi|160900329 | 28,066 | 5.34 | +6.28 | NS | NS | −2.59 | NS | +3.77 | +4.23 | S, T |
| Phosphorus metabolic process (GO:0006793) | ||||||||||||
| 687 | Inorganic diphosphatase | gi|160900311 | 19,368 | 4.96 | NS | NS | NS | +1.43 | +2.02 | NS | NS | T, I |
| Cell redox homeostasis | ||||||||||||
| 734 | Redoxin domain-containing protein | gi|160895850 | 20,383 | 5.63 | NS | NS | NS | NS | −2.78 | NS | NS | S, T, I |
| Transaminase activity (GO:0008483) | ||||||||||||
| 319 | Class V aminotransferase | gi|160896522 | 41,574 | 6.08 | NS | NS | NS | −1.96 | −6.12 | −2.05 | −4.33 | S, T, I |
| Ion bonding (GO:0043167) | ||||||||||||
| 416 | Hypothetical protein (ferritin-like superfamily of di-iron-containing four-helix-bundle protein) | gi|160901296 | 34,343 | 4.86 | +3.97 | NS | NS | −2.45 | −2.71 | +2.23 | +2.26 | S, T |
| Others/unknown | ||||||||||||
| 595 | Glutathione | gi|160896300 | 23,088 | 6.17 | NS | NS | NS | NS | +2.41 | +1.73 | NS | S, T, I |
| 808 | Ribosomal subunit interface protein | gi|160896367 | 13,610 | 5.51 | −1.96 | NS | NS | NS | −1.96 | −1.87 | −2.64 | S, T |
| 46 | AMP-binding domain-containing protein | gi|160901406 | 63,817 | 5.63 | NS | NS | −1.62 | −4.47 | −7.14 | −3.13 | −2.98 | S, T, I |
| 714 | Phasin family protein | gi|160900174 | 19,110 | 5.43 | −2.35 | −2.14 | −2.11 | NS | NS | NS | NS | S, T, I |
GO, gene ontology ID.
Fold change in protein expression from the respective control biofilms. Minus and plus signs indicate decreased and increased expression. NS, not significant.
S, strain (WT15 and MT51); T, treatment (0, 10, and 30 μg ml−1); I, interaction.
FIG 5 Gene ontology cluster (DAVID) analysis of proteins up-regulated (blue) and down-regulated (red) in WT15 and MT51 biofilms treated with chlorhexidine at 10 and 30 µg/ml showing the biological, molecular, and cellular processes that were affected. The proteins were picked from the Deep Purple-stained pick gel and analyzed by mass spectrometry.